AIM: To investigate the effects of antireflux treatment on bronchial hyper-responsiveness and lung function in asthmatic patients with gastroesophageal reflux disease (GERD). METHODS:Thirty asthmatic patients with GERD were randomly divided into two groups (group A and group B). Patients in group A (n=15) only received asthma medication including inhaled salbutamol 200 microg four times a day and budesonide 400 microg twice a day for 6 weeks. Patients in Group B (n=15) received the same medication as group A, and also antireflux therapy including oral omeprazole 20 mg once a day and domperidone 10 mg three times a day for 6 weeks. Pulmonary function tests and histamine bronchoprovocation test were performed before and after the study. RESULTS: There was no significant difference in the baseline values of pulmonary function and histamine PC(20-FEV1) between the two groups. At the end of the study, the mean values for VC, VC%, FVC, FVC%, FEV(1), FEV(1)%, PEF, PEF%, PC(20-FEV1) were all significantly improved in group B, compared with group A. CONCLUSION:Antireflux therapy may improve pulmonary function and inhibit bronchial hyper-responsiveness in asthmatic patients with GERD.
RCT Entities:
AIM: To investigate the effects of antireflux treatment on bronchial hyper-responsiveness and lung function in asthmatic patients with gastroesophageal reflux disease (GERD). METHODS: Thirty asthmatic patients with GERD were randomly divided into two groups (group A and group B). Patients in group A (n=15) only received asthma medication including inhaled salbutamol 200 microg four times a day and budesonide 400 microg twice a day for 6 weeks. Patients in Group B (n=15) received the same medication as group A, and also antireflux therapy including oral omeprazole 20 mg once a day and domperidone 10 mg three times a day for 6 weeks. Pulmonary function tests and histamine bronchoprovocation test were performed before and after the study. RESULTS: There was no significant difference in the baseline values of pulmonary function and histamine PC(20-FEV1) between the two groups. At the end of the study, the mean values for VC, VC%, FVC, FVC%, FEV(1), FEV(1)%, PEF, PEF%, PC(20-FEV1) were all significantly improved in group B, compared with group A. CONCLUSION: Antireflux therapy may improve pulmonary function and inhibit bronchial hyper-responsiveness in asthmatic patients with GERD.
Authors: S Sontag; S O'Connell; H Greenlee; T Schnell; R Chintam; B Nemchausky; G Chejfec; M Van Drunen; J Wanner Journal: Am J Gastroenterol Date: 1987-02 Impact factor: 10.864
Authors: Ana Carla S Araujo; Lílian Rose O Aprile; Roberto O Dantas; João Terra-Filho; Elcio O Vianna Journal: Lung Date: 2008-02-23 Impact factor: 2.584
Authors: Kathryn A Peterson; Wayne M Samuelson; Darin T Ryujin; David C Young; Kristen L Thomas; Kristen Hilden; John C Fang Journal: Dig Dis Sci Date: 2008-08-08 Impact factor: 3.199
Authors: V Mertens; K Blondeau; A Pauwels; R Farre; B Vanaudenaerde; R Vos; G Verleden; D E Van Raemdonck; L J Dupont; D Sifrim Journal: Dig Dis Sci Date: 2009-02-25 Impact factor: 3.199